150 related articles for article (PubMed ID: 29458749)
1. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2018 Feb; 42():7-12. PubMed ID: 29458749
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2016 Sep; 25():16-23. PubMed ID: 27823710
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Allen RP; Earley CJ
Sleep Med; 2021 Aug; 84():179-186. PubMed ID: 34157632
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
Allen RP; Adler CH; Du W; Butcher A; Bregman DB; Earley CJ
Sleep Med; 2011 Oct; 12(9):906-13. PubMed ID: 21978726
[TBL] [Abstract][Full Text] [Related]
5. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome.
Schneider J; Krafft A; Manconi M; Hübner A; Baumann C; Werth E; Gyr T; Bassetti C
Sleep Med; 2015 Nov; 16(11):1342-1347. PubMed ID: 26498233
[TBL] [Abstract][Full Text] [Related]
6. Investigating the response to intravenous iron in restless legs syndrome: an observational study.
Hornyak M; Scholz H; Kiemen A; Kassubek J
Sleep Med; 2012 Jun; 13(6):732-5. PubMed ID: 22503006
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder.
DelRosso LM; Ferri R; Chen ML; Kapoor V; Allen RP; Mogavero MP; Picchietti DL
Sleep Med; 2021 Nov; 87():114-118. PubMed ID: 34562823
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
Trenkwalder C; Winkelmann J; Oertel W; Virgin G; Roubert B; Mezzacasa A;
Mov Disord; 2017 Oct; 32(10):1478-1482. PubMed ID: 28643901
[TBL] [Abstract][Full Text] [Related]
9. Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome.
Park HR; Choi SJ; Joo EY; Allen RP
Sleep Med; 2020 Nov; 75():81-87. PubMed ID: 32853922
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder.
DelRosso LM; Reuter-Yuill LM; Cho Y; Ferri R; Mogavero MP; Picchietti DL
Sleep Med; 2022 Dec; 100():488-493. PubMed ID: 36265207
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose effects on restless legs syndrome and on brain iron in patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Li X; Earley CJ
Sleep Med; 2023 Sep; 109():128-131. PubMed ID: 37437492
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies.
Yang X; Yang B; Ming M; Li S; Wang F; Zhu Z; Ji C; Long J; Hu F; Xu Z; Ren H; Liu B
Sleep Med; 2019 Sep; 61():110-117. PubMed ID: 31395522
[TBL] [Abstract][Full Text] [Related]
13. Iron supplementation for restless legs syndrome - A systematic review and meta-analysis.
Avni T; Reich S; Lev N; Gafter-Gvili A
Eur J Intern Med; 2019 May; 63():34-41. PubMed ID: 30798983
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy and Safety of Intravenous Ferric Carboxymaltose for Treatment of Restless Legs Syndrome: A Multicenter, Randomized, Placebo-controlled Clinical Trial.
Earley CJ; García-Borreguero D; Falone M; Winkelman JW
Sleep; 2024 Apr; ():. PubMed ID: 38625730
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Intravenous Iron Sucrose in Hemodialysis Patients with Restless Legs Syndrome (RLS): A Randomized, Placebo-Controlled Study.
Deng Y; Wu J; Jia Q
Med Sci Monit; 2017 Mar; 23():1254-1260. PubMed ID: 28285317
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
Giorgi L; Asgharian A; Hunter B
Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
19. Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?
Park HR; Choi SJ; Joo EY
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329998
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR; Mason NA; Valaoras TG
Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]